China Takayasu Arteritis Registry (CTA Registry)

Status Recruiting

Clinical Trial Summary

Takayasu arteritis (TA) is a chronic large-vessel vasculitis that mainly affects the aorta and its major branches. The epidemiology and pathophysiology of TA is still unclear in China, although many studies have been done. Our previous study supporting by National Natural Science Foundation of China indicated the cytokines such as hs-CRP, NT-proBNP and tumor necrosis factor-alpha (TNF-α) can be used to monitor TA activity, and HLA gene alleles were associated with TA in Chinese han population. Further investigations with larger samples are needed to fully understand the a pathophysiology of TA. The purpose of this study is to build a Chinese national registry system for TA to obtain real-world information, such as current status of characteristics, diagnosis, disease activity, the severity of disease, treatment and outcomes of Chinese TA patients. To analysis and development of effective disease monitoring and treatment strategies.

Clinical Trial Description

Takayasu arteritis (TA) is a chronic vasculitis that causes inflammation of the aorta and its main branches and is characterized by adventitial thickening and cellular infiltration of the tunica media, with local destruction of vascular smooth muscle cells and elastin. The disease is very rare but most commonly occurs in China. In the last decade, the results of our study indicated that HLA-DPB1, HLA-DQA1, HLA-DQB1 and HLA-DRB1 gene alleles were associated with TA in Chinese Han population. And the clinical features of patients with TA were analyzed. The cytokines such as hs-CRP, NT-proBNP and tumor necrosis factor-alpha (TNF-α) can be used to monitor TA activity. But there are still many unknown fields in TA, such as the epidemiology and pathophysiology. This study is to build a Chinese national registry system for TA to obtain real-world information, such as current status of characteristics, diagnosis, disease activity, the severity of disease, treatment and outcomes of Chinese TA patients. To analysis and development of effective treatment strategies. ;

Study Design

Observational Model: Case-Only, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02964364
Study type	Observational [Patient Registry]
Source	Chinese Academy of Medical Sciences, Fuwai Hospital
Contact	Aimin Dang, MD,PhD
Phone	+8610-88322131
Email	aimindangfw@gmail.com
Status	Recruiting
Phase	N/A
Start date	August 2016
Completion date	July 2026

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04564001` - Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis	Phase 2
Terminated	`NCT04882072` - A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)	Phase 3
Completed	`NCT03750929` - Aerobic Capacity and Strength Exercise in Takayasu's Arteritis	N/A
Recruiting	`NCT04137614` - Drug-coated Balloon for Takayasu Arteritis Associated Renal Artery Stenosis	N/A
Recruiting	`NCT02967068` - VCRC Tissue Repository
Recruiting	`NCT05102448` - Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis	Phase 4
Recruiting	`NCT03893136` - The Registry Study of Takayasu Arteritis in East China
Active, not recruiting	`NCT00006055` - Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases	N/A
Completed	`NCT03096275` - Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis	Phase 3
Recruiting	`NCT04300686` - A Pilot Study in Severe Patients With Takayasu Arteritis.	Phase 4
Recruiting	`NCT04299971` - Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients	Phase 4
Recruiting	`NCT03192878` - Infliximab Biosimilar in Takayasu's Arteritis	N/A
Active, not recruiting	`NCT04071691` - PET Imaging of Giant Cell and Takayasu Arteritis
Recruiting	`NCT05904301` - Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases
Completed	`NCT02101333` - Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis	Phase 3
Not yet recruiting	`NCT03550781` - Anti-inflammatory Treatment for Inactive Takayasu Arteritis	Phase 2/Phase 3
Active, not recruiting	`NCT05168475` - Biologics in Refractory Vasculitis	Phase 2
Completed	`NCT03956394` - Takayasu Arteritis Activity Evaluation by Ultrafast Ultrasound Imaging	N/A
Recruiting	`NCT05151848` - Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis	Phase 4
Completed	`NCT03430388` - Yellow Fever Vaccine in Patients With Rheumatic Diseases	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.